becton dickinson compani
aug pm et
summari compani provid wide rang medic devic diagnost product use
hospit doctor offic research lab set
nm price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
jun pm stock trade
expect fy sep sale inclus
 bard bcr acquisit late decemb
rise follow
declin fy due divestitur
respiratori solut unit report
three busi segment medic life
scienc intervent see oper
margin fy fy
devic compani focus vascular
urolog oncolog market
cash share bcr
share total enterpris valu
china one fastest grow market
combin compani lead global
presenc sale oversea includ
china
may earn call commun
organiz design integr
plan acquir bard busi fulli
place expect see gross margin
expand substanti
even
integr cost see oper
ebit margin improv fy
fy fy
fy ep estim
view bcr deal posit see bcr
acceler sale growth expand
margin deal immedi
accret earn expect
gener high-single-digit accret fy
sep estim million
cost synergi fy believ
compani execut acquisit
increas leverag ebitda
end decemb plan de-lev
within three year
encourag strong global demand
safeti diabet care diseas
test product see
sustain revenu gener long
term forward earn think
attract valu
risk opinion target price includ
slower-than-expect realiz synergi
recent acquisit macroeconom
pressur key end market given
target price
ep estim
multipl slightli peer toward
high-end three-year rang
posit view chang
market competit new product
introduct competitor potenti
significantli affect market dynam chang
domest foreign health care industri practic
regul may result increas price pressur
lower reimburs product still
product line favor demand price
characterist medic equip
industri gener
nov ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
becton dickinson compani
corpor overview becton dickinson compani global medic technolog compani
engag develop manufactur sale broad rang medic suppli devic
laboratori equip diagnost product use healthcar institut life scienc research
clinic laboratori pharmaceut industri gener public one first
compani sell -made glass syring pioneer product hypoderm needl
tradit two busi segment bd medic bd life scienc decemb
acquisit bard bcr compani began report third segment bd
quarter end march gener billion revenu break-out
billion medic segment billion life scienc billion
intervent bdx year end septemb
bd medic segment produc broad array medic technolog devic use help
improv healthcar deliveri wide rang set primari custom serv bd medic
hospit clinic physician offic practic consum retail pharmaci government
nonprofit public health agenc pharmaceut compani healthcar worker organiz
unit segment diabet care medic procedur solut medic manag
solut pharmaceut system exampl product includ syring pen needl intraven
cathet medic deliveri infus therapi deliveri system pre-fil drug deliveri system
bd life scienc segment provid product safe collect transport diagnost
specimen instrument reagent system detect broad rang infecti diseas
healthcare-associ infect cancer addit bd life scienc produc research clinic
tool facilit studi cell compon cell gain better understand
normal diseas process inform use aid discoveri develop new
drug vaccin improv diagnosi manag diseas primari custom
serv segment hospit laboratori clinic blood bank healthcar worker public
health agenc physician offic practic academ govern institut pharmaceut
biotechnolog compani organiz unit segment preanalyt system
diagnost system bioscienc
bd intervent segment includ major formerli bard product offer
certain product offer formerli report medic segment intervent
segment broken three organiz unit surgeri peripher intervent urolog critic
care unit includ product hernia soft tissu repair biolog graft cathet drug
coat balloon cancer diagnost
impact major develop decemb close acquisit bard inc bcr
total enterpris valu billion bcr lead develop manufactur market
medic technolog field vascular urolog oncolog surgic specialti acquisit
substanti chang product mix bcr product faster grow clinic area
deal also boost alreadi sizeabl presenc china acquisit
start report new segment bd intervent includ major bcr product
offer integr probabl difficult given scale adjust organiz
design design integr plan
last sizeabl acquisit prior bcr carefus cfn march acquir cfn
lead provid medic devic diagnost product billion acquisit
departur histori bolt-on acquisit integr larg complet may
three year acquisit
financi trend fiscal year end septemb revenu declin year-over-year
billion five-year cumul annual growth rate compound-annual-growth-rate normal ep
five-year compound-annual-growth-rate fy normal ep vs fy
march net debt total capit ratio leverag ratio net debt
ebitda debt level elev primarili bcr acquisit commit
de-lever within three year compani indic could pay debt
quicker leav flexibl opportunist tuck-in acquisit
senior vice-president corpor
execut vice-president global
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
base cfra proprietari quantit model
stock rank overvalu
bullish sinc june technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
stop medicaid expans senat
fail multipl time gather
suffici number vote pass variou
repeal replac bill howev republican
success elimin individu
mandat passag tcja
decemb see develop
neg health care equip
compani fewer insur patient
futur like lead fewer procedur
expect hospit largest
consum medic equip
advers impact could pressur
sale medic equip compani
includ increas global demand
qualiti health care age popul
rise outlay lead steadi flow
new diagnost therapeut product
 health equip
sub-index increas vs rise
 composit index year
date june health
increas composit index
fundament outlook health care
equip sub-industri next month
posit continu expect
compani sub-industri grow
addit sub-industri mani product
area histor
use non-elect procedur
constant currenc basi expect
revenu sub-industri rise
high-single-digit low-double-digit
percentag driven continu pipelin
expans acquisit speed
new product come market
increas recent year
success effort food drug
administr fda reduc approv
time medic devic time
see price pressur incess head wind
medic equip compani although
hospit saw boost cash tcja
tax cut job act think
hospit cautiou capit
budget amid on-going shift value-bas
care loom roll-off
medic devic tax sought rais
total billion year took
effect mani compani implement
cost optim measur respons
medic devic excis tax suspend
sinc begin
suspend till end compani
health care equip sub-industri stand
benefit medic devic tax repeal
develop
question opinion
recent republican administr
 difficulti attempt
repeal afford act
base index
five-year market price perform aug
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
compani rais target in-lin
peer fy sept ep estim sept- ep
estim sale account divestitur
pro forma sale rose bd life scienc rose stand-alon
basi see fy sept sale growth ep
pend acquisit cr bard bcr track
close fourth quarter calendar /jeffrey loo cfa
compani rais target price
in-lin peer forward ep estim jun-q
ep vs in-lin ahead estim rais fy
sep ep estim sale divestitur
respiratori solut unit fell pro forma basi sale rose
bd medic sale pro forma basi rose bd life scienc rose
pend acquisit cr bard track close fourth
quarter calendar year see deal acceler sale margin
et cfra rais opinion share becton dickinson buy
hold agre buy cr bard bcr
lead devic firm vascular urolog oncolog share
consist cash share bcr share
combin compani lead global presenc medic
manag infect prevent vascular surgic specialti
sale includ china view deal posit
see bcr acceler sale expand margin rais
target slightli peer ep estim
/jeffrey loo cfa
analyst research note compani news
et cfra keep buy opinion share becton dickinson
compani maintain target
ep estim multipl near high-end
five-year rang slightli peer averag jun-q
ep vs higher estim rais
sep ep jun-q sale increas billion
driven acquisit organ basi revenu grew medic
segment grew life scienc intervent
encourag bard integr activ proceed plan
manag confid achiev million cost synergi
lower gross leverag debt-ebitda
march decemb juli made tuck-in
acquisit tva medic compani develop minimally-invas
solut patient chronic kidney diseas think
technolog could signific opportun /kevin huang cfa
compani rais target
next-twelve-month ep estim multipl near
high-end bdx three-year rang slightli
peer averag mar-q ep vs higher
estim rais sep ep estim
ep mar-q sale increas
billion driven dec acquisit cr bard organ
basi revenu grew compris growth bd medic revenu
growth bd life scienc growth bd intervent
paid million debt mar-q brought gross leverag
debt-ebitda dec commun
organiz design integr plan acquir bard busi
fulli in-plac look forward well execut plan /kevin
et cfra add becton dickinson high qualiti capit
appreci portfolio lead supplier
medic suppli equip devic hospit physician
implement multi-year product portfolio restructur move
faster grow higher margin busi primarili acquisit
divest slower grow lower margin product acquir
carefus decemb acquir cr bard
oper margin expand
see expans replac
compani rais target price
line peer fy sep ep estim
inclus bard set fy dec-q ep vs
ahead estim sale rose bd medic
bd life scienc robust diagnost system sale aid
earlier flu season expect robust sale emerg market
china continu fy look integr
bard lift gross margin bp oper margin bp
set fy sept ep estim
account pend acquisit cr bard bcr
pend divestitur soft tissu core needl biopsi product line
bcr aspira product line expect bcr
acquisit relat divestitur complet shortli reiter
forecast bcr deal acceler sale margin
updat model upon deal complet keep target price
in-lin peer fy ep estim /jeffrey
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd
repres total revenu estim
fiscal year analyst estim earn
per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
becton dickinson compani
